Skip to main navigation
  • Our Company
    • About Us
    • Executive Team
    • Board of Directors
    • Scientific and Clinical Advisors
    • Partners
  • Our Science
    • Overview
    • CD6-ALCAM Pathway
    • Itolizumab
    • Publications
  • Pipeline
    • Overview
    • Pipeline Graphic
    • Clinical Trials
  • Patients
    • Therapeutic Areas
      • Graft-Versus-Host Disease
      • Uncontrolled Moderate to Severe Asthma
      • SLE / Lupus Nephritis
    • Clinical Trials
      • The EQUATE study
      • The EQUIP study
      • The EQUALISE study
  • Investors
    • Investor Overview
    • Stock Quote & Chart
    • Historical Price Lookup
    • News
    • Events & Presentations
    • Analyst Coverage
    • SEC Filings
    • Governance Highlights
    • Committee Composition
    • Investor FAQ
    • Alerts & Contacts
  • Careers
  • Contact Us
    Equillium Bio
    • Our Company
      • About Us
      • Executive Team
      • Board of Directors
      • Scientific and Clinical Advisors
      • Partners
    • Our Science
      • Overview
      • CD6-ALCAM Pathway
      • Itolizumab
      • Publications
    • Pipeline
      • Overview
      • Pipeline Graphic
      • Clinical Trials
    • Patients
      • Therapeutic Areas
        • Graft-Versus-Host Disease
        • Uncontrolled Moderate to Severe Asthma
        • SLE / Lupus Nephritis
      • Clinical Trials
        • The EQUATE study
        • The EQUIP study
        • The EQUALISE study
    • Investors
      • Investor Overview
      • Stock Quote & Chart
      • Historical Price Lookup
      • News
      • Events & Presentations
      • Analyst Coverage
      • SEC Filings
      • Governance Highlights
      • Committee Composition
      • Investor FAQ
      • Alerts & Contacts
    • Careers
    • Contact Us

    News

    Investor Relations

    • Investor Overview
    • Stock Quote & Chart
    • Historical Price Lookup
    • News
    • Events & Presentations
    • Analyst Coverage
    • SEC Filings
    • Governance Highlights
    • Committee Composition
    • Investor FAQ
    • Alerts & Contacts

    News

    January 22, 2021
    Equillium Announces Acceptance of Late-Breaking Abstract for Oral Presentation of Interim Data from EQUATE Study in acute GVHD at the 2021 TCT Meetings Digital Experience
    January 22, 2021
    Equillium Announces Acceptance of Late-Breaking Abstract for Oral Presentation of Interim Data from EQUATE Study in acute GVHD at the 2021 TCT Meetings Digital Experience
    January 5, 2021
    Equillium to Present at the H.C. Wainwright Virtual BioConnect Conference
    2021 © Equillium, Inc. EDPO Certification | Privacy Notice
    Scroll to top